Skip to content

Long Term Cardiac Health Effects In Pulmonary TB

Long Term Cardiac And Pulmonary Consequences Of TB (LONG TB) - LONG TB

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097891
Enrollment
350
Registered
2025-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J984- Other disorders of lung

Interventions

Intervention1: NIL: NIL Intervention2: Nil: Nil

Sponsors

National Institutes of Health NIH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Adults more thab 18 years of age 2 Xpert Ultra PTB -MTB detected and subsequently confirmed by MTB culture 3 Ability and willingness to provide informed consent, including consent for blood and sputum collection and storage for future research

Exclusion criteria

Exclusion criteria: 1 More than 7 days of TB treatment for current TB episode 2 Prior history of TB, regardless of treatment duration 3 Multi- or extensively-drug resistant pulmonary TB, or poly-resistant pulmonary TB 4 Extra-pulmonary TB without microbiologically confirmed pulmonary involvement 5 Prior physician diagnosis of any chronic lung disease or cardiovascular disease 6 Pregnant women or those who plan to get pregnant during the study period 7 Severe illness which, in the study clinician s judgement, will interfere with the participants ability to complete all study visits

Design outcomes

Primary

MeasureTime frame
The primary outcomes will focus on persistent PTLD and sub-clinical CVD, with secondary outcomes including changes in lung function and cardiovascular parameters. This study aims to fill critical knowledge gaps and establish a valuable resource for future research on post-TB sequelae.Timepoint: 0 week, 6 months and 12months

Secondary

MeasureTime frame
Secondary outcomes will include changes in lung function, 6 min walk distance, respiratory questionnaire scores, & quantitative imaging parameters. For Aim 2, the primary outcome will be persistent sub-clinical CVD, identified through various cardiovascular assessments. Secondary outcomes will include changes in ejection fraction, carotid intima-media thickness, & pulmonary artery systolic pressure.Timepoint: 0 week, 6 months & 12months

Countries

India, Philippines, South Africa, Uganda

Contacts

Public ContactDevasahayam J Christopher

Christian Medical College, Vellore

djchris@cmcvellore.ac.in09443306573

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026